This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [01.10.2019] – [With additional studies] sallieq | home:food:aim_health:aging [01.11.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 6: | Line 6: | ||
taken from article [[home: | taken from article [[home: | ||
- | ===== With additional studies ===== | + | ===== with additional studies ===== |
- | benefits | + | Benefits |
- | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | + | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> |
+ | | ||
+ | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
+ | |||
+ | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
+ | |||
+ | Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| |